Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bicara Therapeutics Inc. - Common Stock (NQ: BCAX )

15.51 UNCHANGED
Streaming Delayed Price Updated: 10:22 AM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 19,607
Open 15.36
Bid (Size) 15.36 (2)
Ask (Size) 15.60 (3)
Prev. Close 15.51
Today's Range 14.58 - 15.60
52wk Range 8.910 - 28.09
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
From Bicara Therapeutics Inc.
Via GlobeNewswire
This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga

Performance

YTD
-8.36%
-8.36%
1 Month
+12.39%
+12.39%
3 Month
+30.12%
+30.12%
6 Month
-31.01%
-31.01%
1 Year
-33.75%
-33.75%

More News

Read More
Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Bicara Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025
From Bicara Therapeutics Inc.
Via GlobeNewswire
Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
From Bicara Therapeutics Inc.
Via GlobeNewswire
Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
From Bicara Therapeutics Inc.
Via GlobeNewswire
Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium
From Bicara Therapeutics Inc.
Via GlobeNewswire
Why Versus Systems Shares Are Trading Higher By Around 71%; Here Are 20 Stocks Moving Premarket
Via Benzinga
BioAge Labs, Riot Platforms And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Bicara Therapeutics Inc.
Via GlobeNewswire
Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference
From Bicara Therapeutics Inc.
Via GlobeNewswire
This Wells Fargo Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Via Benzinga
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
StandardAero Surges In Market Debut
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Bicara Therapeutics Inc.
Via GlobeNewswire
Trio Of Biotech IPOs Climb In Debut
Via Talk Markets
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.